Shots:

• The company initiates a P-III EVERGREEN study to evaluate the efficacy- safety & immunogenicity of RSV vaccine vs PBO in 23000 adults aged ≥60yrs. with LRTD caused by RSV across North America- EU- Africa- America & Asia
• The positive P-IIb CYPRESS data further supports the initiation of the P-III EVERGREEN study & the results from the P-IIb CYPRESS study will be presented at IDWeek 2021
• In Sep’19- the RSV vaccine has received the BTD from the US FDA to prevent LRTD caused by RSV in adults aged ≥60yrs. In Nov’20- the EMA’s CHMP has recommended the vaccine for the PRIME designation based on the clinical data

  Ref: J&J | Image: Janssen